Agenda I status undoubtedly enhances the volume of complexity for just about any investigation study. One example is, all researchers—whether or not preclinical or clinical—have to acquire Program I research registrations. 21 CFR section 1301.18. By contrast, researchers who have DEA Practitioner registrations in Schedules II–V (which most ph